目的： 探讨RhoA和Ezrin在乳腺浸润性导管癌中的表达及其临床意义。 方法： 选用2008年1月至12月河北医科大学第四医院收治的乳腺浸润性导管癌患者术后石蜡标本86例。免疫组织化学染色检测肿瘤组织中RhoA和Ezrin的表达情况，分析其临床病理意义及两者的相关性。 结果： 86例乳腺浸润性导管癌组织中，RhoA的阳性表达率为60.47%，显著高于乳腺正常导管上皮组织的20%（P<0.05）；Ezrin的强阳性表达率为65.12%，显著高于乳腺正常导管上皮组织（P<005）。乳腺浸润性导管癌组织中RhoA的阳性表达和Ezrin的强阳性表达与患者年龄无关（P>0.05），与腋淋巴结转移、组织学分级和TNM分期有关（均P<005）。乳腺浸润性导管癌组织中RhoA的阳性表达和Ezrin的强阳性表达呈正相关（P<001）。 结论： 乳腺浸润性导管癌高表达RhoA和Ezrin，并在导管癌的发生、发展过程中发挥作用。

Objective : To investigate the expressions of RhoA and Ezrin in breast infiltrating ductal carcinoma (BIDC) and their clinical significances. Methods: Eighty-six BIDC paraffin samples were obtained from Fourth Hospital of Hebei Medical University (Jan. 2008 to Dec. 2008). Immunohistochemical method was used to assess the expression of RhoA and Ezrin in tumor tissues. The relationship between RhoA and Ezrin expressions with the clinicopathological parameters was also analyzed. Results: The expression of RhoA and the strong expression of Ezrin in the 86 BIDC samples were 6047% and 65.12%, respectively, which were both significantly higher than those in normal ductal epithelium groups (all P<0.05). Neither the expression of RhoA nor the strong expression of Ezrin was correlated with patient’s age (P>0.05), and they were positively correlated with the axillary lymph node metastasis, histological grades, and TNM stages (all P<0.05). A significant correlation was also found between the expression of RhoA and the strong expression of Ezrin in BIDC samples (P<0.01). Conclusion: RhoA and Ezrin are highly expressed in IBDC tissues, and may play important roles in the carcinogenesis and progression of BIDC.

河北省青年自然科学基金资助项目（No.C2009001212）；河北省普通高校强势特色学科资助项目（No.200552）；河北省卫生厅科研基金项目（No. 20090487）